ArticleCancer management and research2018
Prognostic value of
Article in Cancer management and research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- EGFR Mutations and Recurrence Outcomes in Resected Non-Small Cell Lung Cancer: An Updated 2015-2025 Systematic Review and Meta-Analysis.Thoracic cancer · 2026Pooled it
- Review
- Assessing mutation-clinical correlations and treatment outcomes in Vietnamese non-small cell lung cancer patients.Practical laboratory medicine · 2025Article
- Clinical significance of DNA damage response mutations in stage I and stage IIIa NSCLC.Thoracic cancer · 2023Article
- Characteristics and prognostic analysis of patients with detectedTranslational lung cancer research · 2023Article
- Disparity and Diversity in NSCLC Imaging and Genomics: Evaluation of a Mature, Multicenter Database.Cancers · 2023Article
- Matrix Metallopeptidase-Gene Signature Predicts Stage I Lung Adenocarcinoma Survival Outcomes.International journal of molecular sciences · 2023Article
- [Consensus on Postoperative Recurrence Prediction of Non-small Cell Lung Cancer Based on Molecular Markers].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2022Article
- Lipid Droplets in Lung Cancers Are Crucial for the Cell Growth and Starvation Survival.International journal of molecular sciences · 2022Article
- Combination of epidermal growth factor receptor mutation and the presence of high-grade patterns is associated with recurrence in resected stage I lung adenocarcinoma.Interactive cardiovascular and thoracic surgery · 2022Article
- Article
- Somatic mutations combined with clinical features can predict the postoperative prognosis of stage IIIA lung adenocarcinoma.Annals of translational medicine · 2022Article
- Epstein-Barr Virus Infection in Lung Cancer: Insights and Perspectives.Pathogens (Basel, Switzerland) · 2022Review
- Real-World Survival Outcomes Based onJTO clinical and research reports · 2022Article
- The role of oncogenes and tumor suppressor genes in determining survival rates of lung cancer patients in the population of North Sumatra, Indonesia.F1000Research · 2022Article
- Neoadjuvant treatment of stage IIIA-N2 inTranslational lung cancer research · 2021Review
- Current therapy of KRAS-mutant lung cancer.Cancer metastasis reviews · 2020Review
- How should molecular findings be integrated in the classification for lung cancer?Translational lung cancer research · 2020Review
- Endothelin-1 rs9296344 associates with the susceptibility of childhood primary nephrotic syndrome.Journal of clinical laboratory analysis · 2020Article
- Identifying relationships between imaging phenotypes and lung cancer-related mutation status: EGFR and KRAS.Scientific reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe prognostic value of
methodsWe searched Internet databases for studies reporting disease-free survival (DFS) and overall survival (OS) in resected NSCLC patients with
resultsA total of 9,635 patients from 32 studies were included in this analysis. The combined HR for
conclusionThe analysis showed that
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.